Moyamoya Disease Causes
Moyamoya Disease Causes
The honest answer to why the artery narrows is that the process is partly characterised and not fully explained. What is known is what happens to the wall of the vessel, that there is a strong genetic susceptibility in East Asian populations, that a minority of patients have an affected relative, and that the same angiographic picture can be produced by a list of other conditions. What is not known is what starts it, and no single mechanism has been shown to account for the whole disease. This page sets out that boundary clearly, because families are frequently told less than this and assume they have been told more.
What happens to the wall of the artery
The change is structural and it is not atherosclerosis. The innermost layer of the artery thickens, with a proliferation of cells and a fragmented and distorted internal elastic lamina, while the muscular layer beneath it becomes thin. The vessel narrows from the inside, and over years it closes. Examined tissue also shows that the small collateral vessels at the base of the brain are abnormal in their own right, with walls that are fragile — which is one reason they bleed.
Two things follow that are worth stating. The first is that this is not a disease of lifestyle: it occurs in children who have no risk factors at all, and nothing the patient did caused it. The second is that it is progressive, and what drives the progression is not understood. Several mechanisms have been investigated — inflammatory and immune signals, growth factors that promote vessel formation, enzymes that remodel the vessel wall — and each has supporting evidence without being sufficient to explain the condition.
The practical consequence of that uncertainty is narrow but real. Because the trigger is unknown, there is nothing to remove and no exposure to avoid that has been shown to change the course. What can be changed is the consequences: the reserve, through surgery, and the triggers that convert a marginal supply into an attack.
Genetics: what is established, and what it means for a family
Three statements are well supported, and they are the ones a family needs. First, familial clustering is real: a first-degree relative is affected in a minority of patients, which is many times the rate expected by chance. Second, a susceptibility variant in a gene called RNF213 has been identified, it is present in a substantial proportion of East Asian patients with the disease, and it is rare in populations outside East Asia — which is part of the explanation for why the condition is commoner in Japan, Korea and China than in Europe or North America. Third, and most important for the question families actually ask: carrying the variant is not the same as having the disease. The great majority of carriers never develop it.
That last point is why testing an asymptomatic child is not a simple yes. A positive result does not say that the child will become ill, and a negative result does not fully exclude later disease in a family where it has occurred. There is also the question of what would be done with the result — which, for a child with no symptoms and normal imaging, is usually interval follow-up, the same as it would be for a child with a family history and no test. Genetic counselling is the right setting for this decision, and it should be offered rather than arranged as a matter of course.
What is unambiguous is this: a child with symptoms should be investigated regardless of family history, and a child with an affected first-degree relative and any compatible symptom — a transient attack, an involuntary movement, an unexplained decline in school performance — should be investigated urgently rather than reassured by the absence of a genetic test.
When it is moyamoya syndrome instead
The same appearance on angiography can arise in the setting of another condition, and when it does the term moyamoya syndrome is used. The list is specific: sickle cell disease, neurofibromatosis type 1, Down syndrome, previous radiotherapy to the head, thyroid disease, and several autoimmune conditions. Atherosclerotic disease can produce the picture in adults as well.
Why the distinction is made is practical rather than taxonomic. The underlying condition usually needs managing on its own account — sickle cell disease has its own treatments that affect the vascular picture, and radiotherapy-induced disease has a different prognosis. And the answer to the family's question about screening relatives is different: a syndrome does not carry the familial risk that the primary disease does.
Who develops it
The condition is several times more common in East Asia than in Europe or North America, and it is reported more often in women than in men. There are two peaks in age at presentation: one in early childhood, around five years of age, and one in adulthood, in the fourth decade. Neither peak is exclusive — it can present at any age, and it does.
Beyond ancestry, sex and age, the established associations are the ones already described: a family history, and the conditions that produce moyamoya syndrome. What is notably absent from the list is anything the patient did. There is no dietary exposure, no activity, and no medication that has been shown to cause it, and the families who need to hear this most are the ones who have spent months looking for something they did wrong.
Four things that are not true
That lifestyle caused it. It occurs in young children with no risk factors, and no exposure has been shown to cause it. Parents frequently search for something they did; there is nothing to find.
That it will certainly be passed on. Most cases are sporadic. A first-degree relative is affected in a minority, and where a susceptibility variant is carried, most carriers never develop the disease. The risk is real and it is elevated, and it is not a prediction.
That medication treats it. Medicines manage symptoms and consequences. None has been shown to stop the narrowing, and a patient who is on medication but not being followed is not being treated.
That surgery means it is over. Revascularisation changes the blood supply and, for most patients, stops the attacks. It does not remove the disease: vessels that have not been revascularised continue to narrow, the other side usually needs surgery, and the treated territory needs confirmation that the new supply has established. A fourth thing follows from these, and it is the one that causes the most damage: that a child will grow out of it. The condition is progressive, and waiting is not neutral.
What to actually ask at the next appointment
Four questions cover most of what matters, and each one has a right answer and an answer that should worry you. Are both sides involved? — if only one is, ask how often the other side will be imaged. Has the reserve been measured? — if it has not, ask whether it should be. Which technique is proposed, and why that one? — the answer should name the patient's age, the vessels, or the presentation, rather than the surgeon's habit. And what would make you operate sooner? — which is the question that establishes whether there is a plan or merely a diagnosis.
A fifth is worth asking for the sake of the years afterwards: how will the patient be followed, and by whom. Because this is a condition measured in decades, the follow-up arrangement is part of the treatment rather than an administrative detail.